Regulators and Merck were accused of knowing Vioxx risks pre-approval. An FDA drug reviewer claimed superiors pressed him to withhold study results showing Vioxx risks. Merck confirmed seeing results showing risk one year before Vioxx was pulled. The SEC and Justice Department instituted civil and criminal investigations into Merck's handling of Vioxx. State attorneys general criticized Merck's return and refund program. New York State's pension fund lost $171 million and filed suit against Merck for misleading shareholders. Merck was criticized for offering 230 executives large severance packages. A Celebrex clinical trial was halted after researchers found risks similar to Vioxx's. 